Abstract 1191P
Background
Thyroid transcription factor-1 (TTF-1), is expressed in thyroid and lung tissue. TTF-1, assessed by immunohistochemistry (IHC), is a specific biomarker for lung adenocarcinoma, and is commonly used to confirm the pulmonary origin of neuroendocrine tumors (NET), as well. The majority of the available data suggest that TTF-1 is a favourable prognostic biomarker for lung adenocarcinomas, whereas its role in lung NET is controversial.
Methods
A multicenter retrospective study, including 155 Lung NET, all surgically removed, all with available IHC assessment for TTF-1.
Results
Median age was 59.5 years (13–86), N= 58 patients (37.4%) were males, N=40 (25.8%) were smokers, N=31 (20%) were atypical carcinoids, N=85 (54.8%) were centrally-located, N=89 (57.4%) were located in the right lung, N=4 patients (2.6%) presented a TNM stage IV at the diagnosis. Mitotic count was ≥2 per 10 high-power field (HPF) in N=35 cases (22.6%), necrosis was present in N=20 (12.9%). Grade 1 was reported in 103 cases (66.5%), whereas Ki-67 was >20% in N=5 (3.2%). TTF-1 was positive in 78 cases (50.3%), cromogranin A in 139 (89.7%) and synaptophysin in 137 (88.4%), respectively. The most common type of surgery was lobectomy in 91 patients (58.7%). Median overall survival (OS) was 46.9 months (0.6–323), median progression-free survival (PFS) was 39.1 months (0.6–323). Statistically significant associations were found between (i) TTF-1 positivity and female sex (p=0.007), and among (ii) TTF-1 positivity and the absence of necrosis (p=0.018). No other relevant associations were detected between TTF-1 and the remaining clinical or pathological variables.
Conclusions
This study highlights that TTF-1 positivity differs according to sex in lung NET patients, with a more common TTF-1 positive staining in female. Moreover, TTF-1 was associated with the absence of necrosis. These data suggest that TTF-1 could potentially represent a gender-related biomarker in this population. Further analyses are needed to establish the value of this observation, and to determine the value of TTF-1 as prognostic biomarker for lung NET.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1129P - Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
Presenter: Marlana Orloff
Session: Poster session 13
1130P - Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Leah Mailly-Giacchetti
Session: Poster session 13
1131P - Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting
Presenter: Mauricio Fernando Ribeiro
Session: Poster session 13
1132P - Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy
Presenter: Aparna Nallagangula
Session: Poster session 13
1133P - SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
Presenter: Luis del Carpio Huerta
Session: Poster session 13
1134P - Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Presenter: Isabella Glitza
Session: Poster session 13
1135P - Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Presenter: Raymond Huang
Session: Poster session 13
1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases
Presenter: Iris Dirven
Session: Poster session 13
1138P - Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Presenter: Lukas Flatz
Session: Poster session 13